摘要
目的观察尤瑞克林联合奥扎格雷钠治疗轻、中度急性脑梗死（ACI）的疗效和安全性。方法将100例轻、中度ACI患者随机分为观察组和对照组，每组各50例。对照组给予奥扎格雷钠氯化钠注射液80mg／100ml，2次／d，观察组在此基础上加用尤瑞克林注射液0．15PNAU／100ml，1次／d，两组均连续治疗2周。结果观察组治疗后的美国国立卫生研究院卒中量表（NIHSS）和日常生活活动能力（mRS）评分均明显低于对照组，且明显低于治疗前，差异均有统计学意义（P〈0．01）。观察组的临床疗效明显优于对照组，差异有统计学意义（u=2．480，P〈0．05）。两组患者均未出现明显不良反应。结论尤瑞克林联合奥扎格雷钠治疗轻、中度急性脑梗死安全、有效，值得临床推广。
Objective To observe the efficacy and safety of kallikrein and sodium ozagrel in treatment of mild, mod- erate acute cerebral infarction （ACI）. Methods 100 patients with mild, moderate ACI were randomly divided into the control and observation group,each group was 50 cases. The control group received injection of sodium ozagrel 80 mg/100 ml,2/d, while the observation group was added the Kallikrein injection 015 PNAU per 100ml, I/d, both for 2 weeks. Results The scores of the NIHSS and mrs after treatment were significantly lower those of the observation. Clinical efficacy of the observa- tion group was superior to that of the control group （ P 〈 0. 05 ）. Both two groups were in the absence of the marked abverse effect. Conclusion Kallikrein and Sodium ozagTel for treatment of mild, moderate acute cerebral infarction proves to be safe and effective, deserving clinical application.
出处
《中国医学创新》
CAS
2011年第32期6-8,共3页
Medical Innovation of China
关键词
急性脑梗死
尤瑞克林
奥扎格雷钠
疗效
Kallikrein
Sodium ozagrel
Acute cerebral infarction
Efficacy
